Aclaris Announces Proposed Public Offering of Common Stock
October 17 2018 - 4:01PM
Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led,
biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet
patient needs in aesthetic and medical dermatology and immunology,
today announced that it intends to offer and sell, subject to
market conditions, shares of its common stock in an underwritten
public offering. All of the shares of common stock to be sold
in the offering will be offered by Aclaris. Aclaris also intends to
grant the underwriters a 30-day option to purchase up to an
additional 15% of the shares of its common stock offered in the
public offering on the same terms and conditions. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering.
Leerink Partners and Evercore ISI are acting as joint
book-running managers for the offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (SEC) on November 2, 2016
and declared effective by the SEC on November 14, 2016. The
offering will be made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website at
www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus, when available, may also be
obtained by contacting Leerink Partners LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110,
telephone: (800) 808-7525, ext. 6132, or by email at
syndicate@leerink.com; or Evercore Group L.L.C., Attention: Equity
Capital Markets, 55 East 52nd Street, 36th Floor, New York, New
York 10055, by telephone at 888-474-0200, or by email at
ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in dermatology, both aesthetic and medical, and
immunology. Aclaris' focus on market segments with no
FDA-approved medications or where treatment gaps exist has resulted
in the first FDA-approved treatment for raised seborrheic keratoses
and several clinical programs to develop medications for the
potential treatment of common warts, alopecia areata, and
vitiligo.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Aclaris Therapeutics, Inc., including
statements about Aclaris’ anticipated public offering and other
statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms or at all and such
other factors as are set forth in the risk factors detailed in
Aclaris’ Annual Report on Form 10-K for the year ended December 31,
2017 and other filings Aclaris makes with the SEC from time to
time. In addition, the forward-looking statements included in this
press release represent Aclaris’ views as of the date hereof.
Aclaris anticipates that subsequent events and developments will
cause Aclaris’ views to change. However, while Aclaris may elect to
update these forward-looking statements at some point in the
future, Aclaris specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing Aclaris’ views as of any date subsequent to the date
hereof.
Contact:
Aclaris ContactMichael Tung, M.D. Senior Vice President
Corporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Media ContactSheila KennedyVice President, Corporate
Communications484-321-5559media@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024